(Q60961159)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

title

Drug development and the FDA's Critical Path Initiative (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Cossman J

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

language of work or name

English

0 references

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

129-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186012%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100014

23 December 2019

exact match

0 references

cites work

The price of innovation: new estimates of drug development costs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Productivity counts--but the definition is key

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Syncope, seizure, or surprise? A teenager's school trip gone awry: case report of torsades de pointes and a review of long QT syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021

Sematech: purpose and performance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100014

7 January 2021